Cargando…
Future Research Priorities for Morbidity Control of Lymphedema
BACKGROUND: Innovation in the treatment of lower extremity lymphedema has received low priority from the governments and pharmaceutical industry. Advancing lymphedema is irreversible and initiates fibrosis in the dermis, reactive changes in the epidermis and subcutis. Most medical treatments offered...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286751/ https://www.ncbi.nlm.nih.gov/pubmed/28216723 http://dx.doi.org/10.4103/0019-5154.198039 |
_version_ | 1782504056018698240 |
---|---|
author | Narahari, S R Aggithaya, Madhur Guruprasad Moffatt, Christine Ryan, T J Keeley, Vaughan Vijaya, B Rajendran, P Karalam, S B Rajagopala, S Kumar, N K Bose, K S Sushma, K V |
author_facet | Narahari, S R Aggithaya, Madhur Guruprasad Moffatt, Christine Ryan, T J Keeley, Vaughan Vijaya, B Rajendran, P Karalam, S B Rajagopala, S Kumar, N K Bose, K S Sushma, K V |
author_sort | Narahari, S R |
collection | PubMed |
description | BACKGROUND: Innovation in the treatment of lower extremity lymphedema has received low priority from the governments and pharmaceutical industry. Advancing lymphedema is irreversible and initiates fibrosis in the dermis, reactive changes in the epidermis and subcutis. Most medical treatments offered for lymphedema are either too demanding with a less than satisfactory response or patients have low concordance due to complex schedules. A priority setting partnership (PSP) was established to decide on the future priorities in lymphedema research. METHODS: A table of abstracts following a literature search was published in workshop website. Stake holders were requested to upload their priorities. Their questions were listed, randomized, and sent to lymphologists for ranking. High ranked ten research priorities, obtained through median score, were presented in final prioritization work shop attended by invited stake holders. A free medical camp was organized during workshop to understand patients’ priorities. RESULTS: One hundred research priorities were selected from priorities uploaded to website. Ten priorities were short listed through a peer review process involving 12 lymphologists, for final discussion. They were related to simplification of integrative treatment for lymphedema, cellular changes in lymphedema and mechanisms of its reversal, eliminating bacterial entry lesions to reduce cellulitis episodes, exploring evidence for therapies in traditional medicine, improving patient concordance to compression therapy, epidemiology of lymphatic filariasis (LF), and economic benefit of integrative treatments of lymphedema. CONCLUSION: A robust research priority setting process, organized as described in James Lind Alliance guidebook, identified seven priority areas to achieve effective morbidity control of lymphedema including LF. All stake holders including Department of Health Research, Government of India, participated in the PSP. |
format | Online Article Text |
id | pubmed-5286751 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-52867512017-02-17 Future Research Priorities for Morbidity Control of Lymphedema Narahari, S R Aggithaya, Madhur Guruprasad Moffatt, Christine Ryan, T J Keeley, Vaughan Vijaya, B Rajendran, P Karalam, S B Rajagopala, S Kumar, N K Bose, K S Sushma, K V Indian J Dermatol Original Article BACKGROUND: Innovation in the treatment of lower extremity lymphedema has received low priority from the governments and pharmaceutical industry. Advancing lymphedema is irreversible and initiates fibrosis in the dermis, reactive changes in the epidermis and subcutis. Most medical treatments offered for lymphedema are either too demanding with a less than satisfactory response or patients have low concordance due to complex schedules. A priority setting partnership (PSP) was established to decide on the future priorities in lymphedema research. METHODS: A table of abstracts following a literature search was published in workshop website. Stake holders were requested to upload their priorities. Their questions were listed, randomized, and sent to lymphologists for ranking. High ranked ten research priorities, obtained through median score, were presented in final prioritization work shop attended by invited stake holders. A free medical camp was organized during workshop to understand patients’ priorities. RESULTS: One hundred research priorities were selected from priorities uploaded to website. Ten priorities were short listed through a peer review process involving 12 lymphologists, for final discussion. They were related to simplification of integrative treatment for lymphedema, cellular changes in lymphedema and mechanisms of its reversal, eliminating bacterial entry lesions to reduce cellulitis episodes, exploring evidence for therapies in traditional medicine, improving patient concordance to compression therapy, epidemiology of lymphatic filariasis (LF), and economic benefit of integrative treatments of lymphedema. CONCLUSION: A robust research priority setting process, organized as described in James Lind Alliance guidebook, identified seven priority areas to achieve effective morbidity control of lymphedema including LF. All stake holders including Department of Health Research, Government of India, participated in the PSP. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5286751/ /pubmed/28216723 http://dx.doi.org/10.4103/0019-5154.198039 Text en Copyright: © 2017 Indian Journal of Dermatology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Narahari, S R Aggithaya, Madhur Guruprasad Moffatt, Christine Ryan, T J Keeley, Vaughan Vijaya, B Rajendran, P Karalam, S B Rajagopala, S Kumar, N K Bose, K S Sushma, K V Future Research Priorities for Morbidity Control of Lymphedema |
title | Future Research Priorities for Morbidity Control of Lymphedema |
title_full | Future Research Priorities for Morbidity Control of Lymphedema |
title_fullStr | Future Research Priorities for Morbidity Control of Lymphedema |
title_full_unstemmed | Future Research Priorities for Morbidity Control of Lymphedema |
title_short | Future Research Priorities for Morbidity Control of Lymphedema |
title_sort | future research priorities for morbidity control of lymphedema |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286751/ https://www.ncbi.nlm.nih.gov/pubmed/28216723 http://dx.doi.org/10.4103/0019-5154.198039 |
work_keys_str_mv | AT naraharisr futureresearchprioritiesformorbiditycontroloflymphedema AT aggithayamadhurguruprasad futureresearchprioritiesformorbiditycontroloflymphedema AT moffattchristine futureresearchprioritiesformorbiditycontroloflymphedema AT ryantj futureresearchprioritiesformorbiditycontroloflymphedema AT keeleyvaughan futureresearchprioritiesformorbiditycontroloflymphedema AT vijayab futureresearchprioritiesformorbiditycontroloflymphedema AT rajendranp futureresearchprioritiesformorbiditycontroloflymphedema AT karalamsb futureresearchprioritiesformorbiditycontroloflymphedema AT rajagopalas futureresearchprioritiesformorbiditycontroloflymphedema AT kumarnk futureresearchprioritiesformorbiditycontroloflymphedema AT boseks futureresearchprioritiesformorbiditycontroloflymphedema AT sushmakv futureresearchprioritiesformorbiditycontroloflymphedema |